Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Dodd RY, Crowder LA, Haynes JM, Notari EP, Stramer SL, Steele WR. Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016. Transfus Med Rev 2020;34:81-93. [PMID: 32178888 DOI: 10.1016/j.tmrv.2020.02.001] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 02/10/2020] [Accepted: 02/11/2020] [Indexed: 12/20/2022]

For:	Dodd RY, Crowder LA, Haynes JM, Notari EP, Stramer SL, Steele WR. Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016. Transfus Med Rev 2020;34:81-93. [PMID: 32178888 DOI: 10.1016/j.tmrv.2020.02.001] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 02/10/2020] [Accepted: 02/11/2020] [Indexed: 12/20/2022]

Number

Cited by Other Article(s)

Melemenidis S, Nguyen KD, Baraceros-Pineda R, Barclay CK, Bautista J, Lau HD, Ashraf MR, Manjappa R, Dutt S, Soto LA, Katila N, Lau B, Viswanathan V, Yu AS, Surucu M, Skinner LB, Engleman EG, Loo BW, Pham TD. Rapid Sterilization of Clinical Apheresis Blood Products Using Ultra-High Dose Rate Radiation. Int J Mol Sci 2025;26:2424. [PMID: 40141066 PMCID: PMC11942528 DOI: 10.3390/ijms26062424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2025] [Revised: 02/28/2025] [Accepted: 03/03/2025] [Indexed: 03/28/2025] Open

Affiliation(s)

Stavros Melemenidis Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Khoa D. Nguyen Stanford Blood Center, Stanford Health Care, Stanford, CA 94304, USA; (K.D.N.); (C.K.B.); (J.B.); (E.G.E.)
Rosella Baraceros-Pineda Department of Health Policy, Center for Innovation to Implementation, Veterans Affairs Health Care, Palo Alto, CA 94304, USA;
Cherie K. Barclay Stanford Blood Center, Stanford Health Care, Stanford, CA 94304, USA; (K.D.N.); (C.K.B.); (J.B.); (E.G.E.)
Joanne Bautista Stanford Blood Center, Stanford Health Care, Stanford, CA 94304, USA; (K.D.N.); (C.K.B.); (J.B.); (E.G.E.)
Hubert D. Lau Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA;
M. Ramish Ashraf Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Rakesh Manjappa Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Suparna Dutt Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Luis A. Soto Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Nikita Katila Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Brianna Lau Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Vignesh Viswanathan Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Amy S. Yu Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Murat Surucu Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Lawrie B. Skinner Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.)
Edgar G. Engleman Stanford Blood Center, Stanford Health Care, Stanford, CA 94304, USA; (K.D.N.); (C.K.B.); (J.B.); (E.G.E.) Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA Division of Immunology & Rheumatology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
Billy W. Loo Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (S.M.); (M.R.A.); (R.M.); (S.D.); (L.A.S.); (N.K.); (B.L.); (V.V.); (A.S.Y.); (M.S.); (L.B.S.); (B.W.L.) Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
Tho D. Pham Stanford Blood Center, Stanford Health Care, Stanford, CA 94304, USA; (K.D.N.); (C.K.B.); (J.B.); (E.G.E.) Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA;

Collapse

Raquib A, Salman A, Ziaulhaq A, Al-Mamun F, Shaikh Y, Raquib R, Khan FR, Papatheodorou SI, Mamun MA. Geospatial Distribution of HIV Seroprevalence Among Blood Donors in South Asian Countries: A Systematic Review and Meta-Analysis. AIDS Behav 2025;29:689-701. [PMID: 39601996 DOI: 10.1007/s10461-024-04551-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2024] [Indexed: 11/29/2024]

Kopacz A, Kubicka-Russel D, Liszewski G, Sulkowska E, Chrzanowska A, Zwolińska P, Noceń E, Potępa A, Łętowska M, Grabarczyk P. Hepatitis B Virus in Polish Blood Donors in the Period 2005-2019-Significant Changes in Epidemiology and Demographic Characteristics of Infected Donors. Viruses 2025;17:60. [PMID: 39861849 PMCID: PMC11768870 DOI: 10.3390/v17010060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2024] [Revised: 12/20/2024] [Accepted: 12/24/2024] [Indexed: 01/27/2025] Open

Abstract

In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994-1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000-2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman's coefficient R = -0.98 and R = -0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = -0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21-50 years than in donors ≤20 years, most often in the 41-50 age group. The frequency of OBI increased with donor age and was the highest in the 51-60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.

Collapse

Affiliation(s)

Aneta Kopacz Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Dorota Kubicka-Russel Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Grzegorz Liszewski Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Ewa Sulkowska Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Anna Chrzanowska Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Paulina Zwolińska Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Ewa Noceń Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Anna Potępa Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
Magdalena Łętowska Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland;
Piotr Grabarczyk Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; (D.K.-R.); (G.L.); (E.S.); (A.C.); (P.Z.); (E.N.); (A.P.); (P.G.)
the Group of Polish Blood Transfusion Centers for Blood Borne Pathogens

Collapse

Melemenidis S, Nguyen KD, Baraceros-Pineda R, Barclay CK, Bautista J, Lau H, Ashraf MR, Manjappa R, Dutt S, Soto LA, Katila N, Lau B, Visvanathan V, Yu AS, Surucu M, Skinner LB, Engleman EG, Loo BW, Pham TD. Rapid Sterilization of Clinical Apheresis Blood Products using Ultra-High Dose Rate Radiation. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.12.14.628469. [PMID: 39713317 PMCID: PMC11661200 DOI: 10.1101/2024.12.14.628469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/24/2024]

Affiliation(s)

Stavros Melemenidis Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Khoa D. Nguyen Stanford Blood Center, Stanford Health Care, Stanford, California, USA
Rosella Baraceros-Pineda Department of Health Policy, Center for Innovation to Implementation, Veterans Affairs Health Care, Palo Alto, California, USA
Cherie K. Barclay Stanford Blood Center, Stanford Health Care, Stanford, California, USA
Joanne Bautista Stanford Blood Center, Stanford Health Care, Stanford, California, USA
Hubert Lau Department of Health Policy, Center for Innovation to Implementation, Veterans Affairs Health Care, Palo Alto, California, USA Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
M. Ramish Ashraf Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Rakesh Manjappa Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Suparna Dutt Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Luis Armando Soto Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Nikita Katila Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Brianna Lau Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Vignesh Visvanathan Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Amy S. Yu Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Murat Surucu Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Lawrie B. Skinner Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
Edgar G. Engleman Stanford Blood Center, Stanford Health Care, Stanford, California, USA Department of Pathology, Stanford University School of Medicine, Stanford, California, USA Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA Division of Immunology & Rheumatology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, California, USA
Billy W. Loo Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA
Tho D. Pham Stanford Blood Center, Stanford Health Care, Stanford, California, USA Department of Pathology, Stanford University School of Medicine, Stanford, California, USA

Collapse

Xie J, Li Z, Liang H, Huang Z, Du R, Gao W, Huang B, Liao F, Rong X, Fu Y, Nie Y, Liang H, Wang H. Prevalence, incidence, and residual risk for human immunodeficiency virus among blood donors from 2003 to 2022 in Guangzhou, China. Transfusion 2024;64:2157-2167. [PMID: 39387542 DOI: 10.1111/trf.18025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2024] [Revised: 08/24/2024] [Accepted: 09/03/2024] [Indexed: 10/15/2024]

Zhang Q, Mei Z, Wei L, Liu D, Xie C, Xu Y. Prevalence and Trends of Transfusion-Transmissible HBV Infection Among Blood Donors in Southwestern China: A Six-Year Retrospective Study. Int J Gen Med 2024;17:3907-3918. [PMID: 39257611 PMCID: PMC11385688 DOI: 10.2147/ijgm.s472609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2024] [Accepted: 08/17/2024] [Indexed: 09/12/2024] Open

Abstract

Objective

Hepatitis B virus (HBV) infection is a significant global public health concern, with variable prevalence rates across regions. The prevalence of transfusion-transmitted HBV infection (TT-HBV) via donated blood necessitates an evaluation of blood safety and potential risks to the population. This study assessed the prevalence of HBV infection among blood donors in Southwestern China over 6 years.

Methods

We analyzed 903,023 blood donations from a central blood center in Southwestern China between January 2017 and December 2022. The prevalence of HBV in donations was determined for one-time and repeat donors, considering birth cohorts and covariates. Demographic characteristics, donation frequency, and anti-HBV antibody status were analyzed to estimate the incidence of TT-HBV.

Results

One-time donors provided 47.78% of the samples, and 52.22% were from repeat donors. The HBV prevalence decreased from 1.0% in 2017 to 0.87% in 2022 in one-time donors and from 0.30% to 0.09%, respectively, in repeat donors. A significantly lower HBV prevalence was identified in the post-1992 birth cohort (0.33%) than in the pre-1992 birth cohort (1.67%). The estimated incidences of TT-HBV occurring from one-time donors, repeat donors, post-1992 birth cohort donors, and pre-1992 birth cohort donors were 20.76, 13.84, 0.82, and 20.98 per 104 person-years, respectively.

Conclusion

Our findings indicate a decreasing trend in HBV prevalence among blood donors in Southwestern China over the 6-year study period. This decline may be attributed to the widespread administration of HBV vaccinations and stringent screening measures implemented by blood donation centers. Continuous monitoring for HBV among blood donors is necessary to evaluate the effectiveness of preventive measures and inform future strategies to reduce transmission.

Collapse

O'Brien SF, Ehsani-Moghaddam B, Osmond L, Fan W, Goldman M, Drews SJ. Epidemiology of Hepatitis C over 28 years of monitoring Canadian blood donors: Insight into a low-risk undiagnosed population. BMC Public Health 2024;24:2319. [PMID: 39192303 PMCID: PMC11348590 DOI: 10.1186/s12889-024-19790-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 08/13/2024] [Indexed: 08/29/2024] Open

Abstract

BACKGROUND

Hepatitis C is a blood-borne infection with the hepatitis C virus (HCV) that can progress to cirrhosis and liver cancer. About 70% (50-80%) of infections become chronic and exhibit anti-HCV and HCV nucleic acid (NAT) positivity. Direct acting oral pan genotypic antiviral treatment became available in 2014 and was free for most Canadians in 2018. Clinical screening for HCV infection is risk-based. About 1% of Canadians have been infected with HCV, with 0.5% chronically infected (about 25% unaware) disproportionately impacting marginalized groups. Blood donors are in good health, are deferred for risks such as injection drug use and can provide insight into the low-risk undiagnosed population. Here we describe HCV epidemiology in first-time blood donors over 28 years of monitoring.

METHODS

All first-time blood donors in all Canadian provinces except Quebec (1993 to 2021) were analyzed. All blood donations were tested for HCV antibodies (anti-HCV) and since late 1999 also HCV NAT. A case-control study was also included. All HCV positive donors (cases) since 2005 and HCV negative donors (1:4 ratio controls) matched for age, sex and location were invited to complete a risk factor interview. Separate logistic regression models for anti-HCV positivity and chronic HCV assessed the association between age cohort, sex, region and neighbourhood material deprivation and ethnocultural concentration.

CASE

control data were analysed by logistic regression.

RESULTS

There were 2,334,238 donors from 1993 to 2021 included. Prevalence for anti-HCV was 0.33% (0.30,0.37) in 1993 and 0.07% (0.05,0.09) in 2021 (p < 0.0001). In 2021 0.03% (0.01,0.04) had chronic HCV. Predictors for both anti-HCV positivity and chronic HCV were similar, for chronic HCV were male sex (OR 1.8, 1.6,2.1), birth between 1945 and 1975 (OR 7.1, 5.9,8.5), living in the western provinces (OR 1.4, 1.2,1.7) and living in material deprived (OR 2.7, 2.1,3.5) and more ethnocultural concentrated neighbourhoods (OR 1.8, 1.3,2.5). There were 318 (35.4%) of chronic HCV positive and 1272 (39.6%) of controls who participated in case control interviews. The strongest risks for acquisition were injection drug use (OR 96.9, 22.3,420.3) and birth in a high prevalence country (OR 24.5, 11.2,53.6).

CONCLUSIONS

Blood donors have 16 times lower HCV prevalence then the general population. Donors largely mirror population trends and highlight the ongoing prevalence of untreated infections in groups without obvious risks for acquisition missed by risk-based patient screening.

Collapse

Elliott S, Flynn E, Mathew S, Hajarizadeh B, Martinello M, Wand H, Ward J. Prevalence of hepatitis C virus exposure and infection among Indigenous and tribal populations: a global systematic review and meta-analysis. Public Health 2024;233:65-73. [PMID: 38850603 DOI: 10.1016/j.puhe.2024.04.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2023] [Revised: 04/23/2024] [Accepted: 04/25/2024] [Indexed: 06/10/2024]

Abstract

OBJECTIVES

The objective of this study was to estimate prevalence of hepatitis C virus (HCV) exposure and infection among Indigenous and tribal populations globally.

STUDY DESIGN

Systematic review and meta-analysis.

METHODS

We systematically searched bibliographic databases and grey literature (1/01/2000-16/06/2022). Prevalence estimates were synthesised overall, by World Health Organization region and HCV-risk group. For studies with comparator populations, prevalence ratios were estimated and pooled.

RESULTS

Ninety-two studies were included. Globally, among general Indigenous and tribal populations, the median prevalence of HCV antibody (HCV Ab) was 1.3% (interquartile range [IQR]: 0.3-3.8%, I2 = 98.5%) and HCV RNA was 0.4% (IQR: 0-1.3%, I2 = 96.1%). The Western Pacific Region had the highest prevalence (HCV Ab: median: 3.0% [IQR: 0.4-11.9%], HCV RNA: median 5.6% [IQR: 2.0-8.8%]). Prevalence was highest in people who injected drugs (HCV Ab: median: 59.5%, IQR: 51.5-67.6%, I2 = 96.6%; and HCV RNA: median: 29.4%, IQR: 21.8-35.2%, I2 = 97.2%). There was no association between HCV Ab prevalence and Indigenous/tribal status for general populations (prevalence ratio = 0.91; 95% CI: 0.56, 1.49) or key risk groups.

CONCLUSIONS

Indigenous and tribal peoples from the Western Pacific Region and recognised at-risk sub-populations had higher HCV prevalence. HCV prevalence showed no association with Indigenous/tribal status. However, this review was limited by heterogeneity and poor quality of constituent studies, varying definitions of Indigenous/tribal status, regional data gaps, and limited studies on chronic infection (HCV RNA). Comprehensive quality evidence on HCV epidemiology in Indigenous and tribal peoples is needed to tailor preventive and treatment interventions so these populations are not left behind in elimination efforts.

Collapse

Quintas AE, Cuboia N, Cordeiro L, Sarmento A, Azevedo L. Seroprevalence of human immunodeficiency virus in African blood donors: a systematic review and meta-analysis. EBioMedicine 2024;105:105210. [PMID: 38941957 PMCID: PMC11260585 DOI: 10.1016/j.ebiom.2024.105210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 05/07/2024] [Accepted: 06/04/2024] [Indexed: 06/30/2024] Open

Abstract

BACKGROUND

In developing countries, the safety of blood transfusions remains an important public health concern as it is associated with a higher risk of transfusion-transmissible infections (TTIs). In this study, we aimed to estimate the seroprevalence of HIV among blood donors in Africa and assess the temporal trends and regional differences within the continent through a systematic review and meta-analysis.

METHODS

Seven electronic databases (PubMed, Web of Science, Cochrane, Scopus, HINARI, Global Index Medicus and Clinical.

TRIAL

gov) were searched for relevant studies for our research. We included all primary studies that estimated the seroprevalence of HIV among blood donors in Africa with an age population from 16 to 65 years old, without language restrictions, from inception up to March 1st 2024. The pooled seroprevalence was estimated through the DerSimonian-Laird random effects model. The temporal trends and regional differences were assessed through subgroup and meta-regression analysis.

FINDINGS

We obtained 122 studies that met our inclusion criteria, comprising 7,814,996 blood donors tested for HIV. Sixty-six percent of the studies were from Western and Eastern Africa. The pooled seroprevalence of HIV among blood donors in Africa was 2.66% (95% CI: 2.17-3.20%; I2 = 99.80%, p < 0.01). The highest prevalence was observed in the Central African region, 3.28% (95% CI: 2.57%-4.06%), followed by the Eastern 3.21% (95% CI: 2.12%-4.52%), and the Western 2.66% (95% CI: 1.93%-3.49%) regions. Lower prevalences were observed in the Northern region, 0.57% (95% CI: 0.0%-2.10%), followed by the Southern African region with 0.45% (95% CI: 0.16%-0.86%). We observed a temporal decreased trend of HIV prevalence.

INTERPRETATION

The prevalence of HIV infection among African blood donors remains high and is not homogeneous across the continent. Efficient measures to strengthen HIV testing and prevent HIV transmission through blood transfusion are needed in Africa. Systematic review protocol registration: PROSPERO CRD42023395616.

FUNDING

This article was supported by National Funds through FCT - Fundação para a Ciência e a Tecnologia,I.P., within CINTESIS, R&D Unit (reference UIDP/4255/2020).

Collapse

Kourout M, Espich S, Fisher C, Tiper I, Purkayastha A, Smith S, Santana-Quintero L, Duncan R. Multiplex detection and identification of viral, bacterial, and protozoan pathogens in human blood and plasma using an expanded high-density resequencing microarray platform. Front Mol Biosci 2024;11:1419213. [PMID: 38966129 PMCID: PMC11222771 DOI: 10.3389/fmolb.2024.1419213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2024] [Accepted: 05/23/2024] [Indexed: 07/06/2024] Open

Conti G, Notari E, Dodd RY, Kessler D, Custer B, Bruhn R, Reik R, Yang H, Whitaker B, Stramer SL. Changes in transfusion-transmissible infection prevalence and demographics among US blood donors during the COVID-19 pandemic. Transfusion 2024;64:1040-1049. [PMID: 38661249 PMCID: PMC11144079 DOI: 10.1111/trf.17851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 04/08/2024] [Accepted: 04/11/2024] [Indexed: 04/26/2024]

Forkin KT, Guinn NR, Warner MA, Panigrahi AK. Addressing Patient Concerns with Blood Transfusion from Donors Vaccinated Against COVID-19: A Clinician Primer. Anesthesiology 2024;140:1020-1025. [PMID: 38457190 DOI: 10.1097/aln.0000000000004913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2024]

Kim HJ, Ko DH. Transfusion-transmitted infections. Blood Res 2024;59:14. [PMID: 38607595 PMCID: PMC11014835 DOI: 10.1007/s44313-024-00014-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 04/04/2024] [Indexed: 04/13/2024] Open

Burananayok S, Nachatri W, Choothanorm P, Kusolthammarat K, Jaruthamsophon K, Yodsawad C, Limsakul P, Charupanit K. COVID-19 impact on blood donor characteristics and seroprevalence of transfusion-transmitted infections in southern Thailand between 2018 and 2022. Sci Rep 2024;14:7920. [PMID: 38575642 PMCID: PMC10995202 DOI: 10.1038/s41598-024-57584-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Accepted: 03/19/2024] [Indexed: 04/06/2024] Open

Chen J, Wang F, Li J, Zuo Q, Wu D, Xiao C. Clinical trial and performance evaluation of the Wantai HBsAg (CMIA) diagnostic kit for screening blood donors in China. Sci Rep 2024;14:1891. [PMID: 38307913 PMCID: PMC10837135 DOI: 10.1038/s41598-024-51910-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 01/11/2024] [Indexed: 02/04/2024] Open

Abstract

In China, according to the 'Technical Operating Procedures for Blood Stations (2019 Edition),' blood stations are authorized to utilize Chemiluminescence Immunoassay (CLIA) to detect pathogen markers linked with transfusion-transmissible infections. However, currently, there is no approved CLIA reagent for the screening of blood-borne diseases in China, specifically for the detection of Hepatitis B surface antigen. The objective of this research project is to conduct a comprehensive evaluation of the performance of the Wantai Chemiluminescent Microparticle Hepatitis B surface antigen reagent. This study evaluates the performance of the Wantai Chemiluminescent Microparticle Immunoassay (CMIA) on the Wan200 + analyzer in screening for Hepatitis B Surface Antigen (HBsAg) in blood samples. The clinical trial component of this evaluation is included as part of the documentation submitted to the National Medical Products Administration (NMPA) of China for the approval of blood screening reagents. The evaluation plan of this study encompasses two main components: clinical trials and performance assessment. We adopted a controlled trial design, utilizing the WanTai Chemiluminescent Microparticle Immunoassay (CMIA) on the Wan200 + analyzer and the Enzyme-Linked Immunosorbent Assay (ELISA) to screen for Hepatitis B Surface Antigen (HBsAg) in routine blood donor samples and reference serum panel samples. To ensure the accuracy of the screening, we additionally employed Abbott's ELISA reagents and HBV DNA for validation. The assessment primarily focused on key performance indicators such as sensitivity, specificity, and analytical sensitivity. Moreover, this clinical trial data has been included as part of the submission to China's National Medical Products Administration (NMPA). In the clinical trials of this study, a total of 10,470 blood donor samples underwent simultaneous testing using both CMIA and ELISA methods. Across two clinical trials, there was remarkable concordance between CMIA and the two ELISA reagents, with Kappa values exceeding 0.82. Among the 269 samples that were double-reactive in the enzyme immunoassay (ELISA) tests, CMIA exhibited a 100% reactivity detection rate. However, CMIA produced 14 and 6 false-positive results in the respective clinical trials, resulting in specificities of 99.73% and 99.89%. In contrast, the specificities for Wantai ELISA and Xin Chuang ELISA were both greater than 99.94%.When testing samples in the gray zone serum plates, CMIA's detection limit significantly exceeded that of the two ELISA assays. CMIA had a detection cutoff of 0.05 IU/mL, while the two ELISA reagents had cutoffs of 0.1 IU/mL and 0.09 IU/mL, respectively. CMIA's detection limits for the adr and adw subtypes were 0.05 IU/mL, and for the ay subtype, it was 0.1 U/mL. The detection limit for 10 HBV mutant samples was 0.5 U/mL. In 165 cases where ELISA tested negative but HBV DNA tested positive, CMIA detected 5 HBsAg-positive samples. This study evaluated the performance of the Wantai CMIA in screening for HBsAg among blood donors. The results demonstrate outstanding performance of CMIA in both clinical trials and performance assessments, detecting all true positive samples with a sensitivity of 100%. It exhibits excellent concordance with the two ELISA assays. Of particular note is its superiority in early detection of HBsAg in the screening of early-stage hepatitis B infections, reducing the window period compared to ELISA. CMIA achieves a specificity exceeding 99.73% for negative blood donors, aligning with the European Union's standards for blood screening assay specificity. In summary, Wantai's CMIA displays high sensitivity and specificity in blood donor screening, making it suitable for screening blood donors in China.

Collapse

Sánchez-Guzmán MDJ, Loyola-Cruz MÁ, López-Ornelas A, Cruz-Cruz C, Durán-Manuel EM, Bello-López JM. In situ and in vitro evaluation of two antiseptics for blood bank based on chlorhexidine gluconate/isopropyl alcohol and povidone-iodine. Transfus Apher Sci 2024;63:103854. [PMID: 38061923 DOI: 10.1016/j.transci.2023.103854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 11/03/2023] [Accepted: 11/22/2023] [Indexed: 03/10/2024]

Abstract

BACKGROUND

Poor disinfection is the main cause of blood contamination, so its elimination is key to limiting the entry of bacteria into the collection system. With the advancement of antiseptic technology, antiseptics with sterile, disposable applicators are now available.

AIM

To evaluate in situ two antiseptics (with and without applicators) for blood banks and to demonstrate in vitro antiseptic activity on bacterial biofilms of importance in transfusion medicine.

METHODS

Antiseptic A (2% sterile solution of chlorhexidine gluconate/70% isopropyl alcohol provided with applicator) and bulk antiseptic B (10% povidone-iodine) were evaluated. The deferred blood donor arms were subjected to disinfection with antiseptics A and B and the contralateral arms were cultured to determine the baseline bacterial load (control). Antiseptic activity was assessed by ANOVA and logaritmic reduction values (LRV) and percentage reduction values (PRV) were calculated. Finally, the in vitro activity of antiseptic A was analyzed by confocal laser scanning microscopy (CLSM) on biofilm models.

RESULTS

Prior to disinfection tests, commensal and clinically important bacteria were identified; antiseptic A showed post-disinfection bacterial growth rates of zero compared to controls (p < 0.0001). The frequency of bacterial growth with antiseptic B was 74%. A significant difference was identified between both antiseptics, where antiseptic A showed higher activity (p < 0.5468). LRV and PRV were 0.6-2.5/100% and 0.3-1.7/66.7-99.7% for antiseptics A and B, respectively. Through CLSM, disinfectant A (without applicator) showed lower in vitro antiseptic activity on the tested biofilms at the exposure times recommended by the manufacturer.

CONCLUSIONS

Sterile solution of chlorhexidine gluconate/isopropyl alcohol with applicator showed advantages disinfection in deferred blood donors over povidone-iodine.

Collapse

Santos APA, Rios DRA, Trindade CLC, Oliveira FEG, Oliveira MB, de Melo SN, Belo VS. Prevalence, incidence, risk factors and residual risk associated with viral infections among eligible Brazilian blood donors. Transfus Med 2024;34:46-53. [PMID: 38165014 DOI: 10.1111/tme.13022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 10/27/2023] [Accepted: 12/12/2023] [Indexed: 01/03/2024]

Young PP, Saa P. Redefining Blood Donation-Path to Inclusivity and Safety. JAMA 2023;330:1841-1842. [PMID: 37824150 DOI: 10.1001/jama.2023.19809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]

Stark CM, Juul SE. New frontiers in neonatal red blood cell transfusion research. J Perinatol 2023;43:1349-1356. [PMID: 37667005 DOI: 10.1038/s41372-023-01757-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 08/06/2023] [Accepted: 08/15/2023] [Indexed: 09/06/2023]

Bloch EM, Busch MP, Corash LM, Dodd R, Hailu B, Kleinman S, O'Brien S, Petersen L, Stramer SL, Katz L. Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases. Transfus Med Rev 2023;37:150769. [PMID: 37919210 PMCID: PMC10841704 DOI: 10.1016/j.tmrv.2023.150769] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 08/22/2023] [Accepted: 08/24/2023] [Indexed: 11/04/2023]

Abstract

The tragedy of transfusion-associated hepatitis and HIV spurred a decades-long overhaul of the regulatory oversight and practice of blood transfusion. Consequent to improved donor selection, testing, process control, clinical transfusion practice and post-transfusion surveillance, transfusion in the United States and other high-income countries is now a very safe medical procedure. Nonetheless, pathogens continue to emerge and threaten the blood supply, highlighting the need for a proactive approach to blood transfusion safety. Blood donor populations and the global transfusion infrastructure are under-utilized resources for the study of infectious diseases. Blood donors are large, demographically diverse subsets of general populations for whom cross-sectional and longitudinal samples are readily accessible for serological and molecular testing. Blood donor collection networks span diverse geographies, including in low- and middle-income countries, where agents, especially zoonotic pathogens, are able to emerge and spread, given limited tools for recognition, surveillance and control. Routine laboratory storage and transportation, coupled with data capture, afford access to rich epidemiological data to assess the epidemiology and pathogenesis of established and emerging infections. Subsequent to the State of the Science in Transfusion Medicine symposium in 2022, our working group (WG), "Emerging Infections: Impact on Blood Science, the Blood Supply, Blood Safety, and Public Health" elected to focus on "leveraging donor populations to study the epidemiology and pathogenesis of transfusion-transmitted and emerging infectious diseases." The 5 landmark studies span (1) the implication of hepatitis C virus in post-transfusion hepatitis, (2) longitudinal evaluation of plasma donors with incident infections, thus informing the development of a widely used staging system for acute HIV infection, (3) explication of the dynamics of early West Nile Virus infection, (4) the deployment of combined molecular and serological donor screening for Babesia microti, to characterize its epidemiology and infectivity and facilitate routine donor screening, and (5) national serosurveillance for SARS-CoV-2 during the COVID-19 pandemic. The studies highlight the interplay between infectious diseases and transfusion medicine, including the imperative to ensure blood transfusion safety and the broader application of blood donor populations to the study of infectious diseases.

Collapse

Laperche S, Sauvage C, Gallian P, Jbilou S, Pouchol E, Py JY, Chabli L, Richard P, Morel P, Lot F, Tiberghien P. Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance. Vox Sang 2023;118:843-853. [PMID: 37694766 DOI: 10.1111/vox.13514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/03/2023] [Accepted: 08/06/2023] [Indexed: 09/12/2023]

Boudreaux J. Transfusion management in thalassemia. Ann N Y Acad Sci 2023;1527:42-48. [PMID: 37531552 DOI: 10.1111/nyas.15049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/04/2023]

Sosa-Jurado F, Palencia-Lara R, Xicoténcatl-Grijalva C, Bernal-Soto M, Montiel-Jarquin Á, Ibarra-Pichardo Y, Rosas-Murrieta NH, Lira R, Cortes-Hernandez P, Santos-López G. Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico. Viruses 2023;15:1331. [PMID: 37376630 DOI: 10.3390/v15061331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 06/01/2023] [Accepted: 06/05/2023] [Indexed: 06/29/2023] Open

Affiliation(s)

Francisca Sosa-Jurado Laboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Atlixco, Puebla 74360, CP, Mexico
Roxana Palencia-Lara Banco de Sangre, Hospital Especialidades, Unidad Médica de Alta Especialidad, Centro Médico Nacional General de División Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla 72000, CP, Mexico
Cinthia Xicoténcatl-Grijalva Laboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Atlixco, Puebla 74360, CP, Mexico
Maribel Bernal-Soto Banco de Sangre, Hospital Especialidades, Unidad Médica de Alta Especialidad, Centro Médico Nacional General de División Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla 72000, CP, Mexico
Álvaro Montiel-Jarquin Coordinación Clínica de Investigación y Enseñanza en Salud, Hospital Especialidades, Unidad Médica de Alta Especialidad, Centro Médico Nacional General de División Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla 72000, CP, Mexico
Yolanda Ibarra-Pichardo Banco de Sangre, Hospital Especialidades, Unidad Médica de Alta Especialidad, Centro Médico Nacional General de División Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla 72000, CP, Mexico
Nora Hilda Rosas-Murrieta Centro de Química, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla 72570, CP, Mexico
Rosalia Lira Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, MX, Mexico
Paulina Cortes-Hernandez Laboratorio de Metadinámica y Salud de Poblaciones, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social (IMSS), Metepec 74360, MX, Mexico
Gerardo Santos-López Laboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Atlixco, Puebla 74360, CP, Mexico

Collapse

Alassad A, Al Rahwanji MJ, Yousfan A, Al Moualem S, Farhat A, Youssef LA. Seroprevalence and trends of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in Syrian blood donors at Damascus University Blood Center between 2004 and 2021. Front Public Health 2023;11:1174638. [PMID: 37325302 PMCID: PMC10267398 DOI: 10.3389/fpubh.2023.1174638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Accepted: 05/12/2023] [Indexed: 06/17/2023] Open

Abstract

Introduction

Seroprevalence of transfusion-transmitted viral infections (TTVIs) is a valuable indicator for assessing blood safety, population health and health system performance in the times of peace and conflicts. Only scarce information is available on the impact of the decade-long violent conflict on the prevalence of TTVIs in Syria. Moreover, hepatitis B vaccine was introduced to the national vaccination program in 1993; however, no data is available on the vaccine effectiveness.

Methods

In this retrospective cross-sectional study, we compiled the screening results for major TTVIs, namely hepatitis B virus (HBV), hepatitis C virus (HCV), and human immuno-deficiency virus (HIV), of volunteer donors at Damascus University Blood Center from May 2004 to October 2021. Prevalence was expressed in percentages for the entire study group and subgroups. Chi-square test and linear regression were used to examine the differences and describe trends in prevalence, respectively, based on demographic characteristics (i.e., age and gender) and time. P-value of <0.005 was considered statistically significant.

Results

Of the total 307,774 donors (82.27% males, median age 27 years), 5,929 (1.93%) had serological evidence of at least one TTVI, and 26 (0.0085%) had multiple infections. The lowest prevalence (1.09%) was detected in donors aged 18-25 years old, and a higher prevalence (2.05%) was evident in males in comparison with females (1.38%). The seroprevalence of HBV, HCV, and HIV was 1.18, 0.52, and 0.23%, respectively. Trend analyses revealed a significant regression in HBV and HIV prevalence from 2011 to 2021. HBV seropositivity depicted a temporal decline by ~80%, from 0.79% in 2011 to 0.16% in 2021 in those born in 1993 and thereafter.

Discussion

The seroprevalence of HBV, HIV, and to a lesser extent HCV dropped over the study 18-year period. Possible explanations may include implementation of the HBV vaccine, robust national health system, conservative sociocultural values, and isolation.

Collapse

Mangala C, Fokam J, Maulot-Bangola D, Rebienot-Pellegrin O, Nkoa T. Genetic diversity of the human immunodeficiency virus of type 1 in Gabonese transfusional settings. BMC Infect Dis 2023;23:191. [PMID: 36997860 PMCID: PMC10061732 DOI: 10.1186/s12879-023-08154-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 03/13/2023] [Indexed: 04/01/2023] Open

Abstract

BACKGROUND

The high endemicity of transfusion-transmissible infections (TTIs) in sub-Saharan Africa is a real public health problem. To reduce the risk of HIV transmission through blood donation, the NBTC of Gabon has launched in recent years a reorganization of its blood transfusion system. This study aims to characterize the molecular strains of HIV-1 circulating in donors and to estimate the risk of viral transmission.

MATERIALS AND METHODS

A cross-sectional study was carried out during the period from August 2020 to August 2021 among 381 donors who had agreed to donate blood at the National Blood Transfusion Center (NBTC). Viral load was determined by Abbott Real-Time (Abbott m2000®, Abbott) and sequencing by the Sanger method (ABI 3500 Hitachi®). The phylogenetic tree was constructed by MEGA X software. Data were checked, entered, and analyzed using SPSS version 21.0 software, with p ≤ 0.05 considered statistically significant.

RESULTS

A total of 381 donors were enrolled in the study. Among the 359 seronegative donors, five (5) seronegative donors were detected positive for HIV-1 using Real-Time PCR. The residual risk was 648 per 1,000,000 donations. The prevalence of residual infection was 1.4% [0,01; 0,03]. Sixteen (16) samples were sequenced. The strains obtained were CRF02_AG (50%), subtype A1 (18.8%), subtype G (12.5%), CRF45_cpx (12.5%) and subtype F2 (6.2%). Six sequences clustered with A1, G, CRF02_AG, and CRF45_cpx subtypes.

CONCLUSION

The residual risk of HIV-1 transmission by blood transfusion remains a concern in the Gabonese transfusional settings. A policy based on improving the current screening strategy would involve the implementation of the nucleic acid test (NAT) in order to optimize the safety of the donation by detecting the HIV-1 subtypes in circulation in the donors.

Collapse

Nakano T, Katayama Y, Sakamoto M, Shimizu Y, Inoie M, Shimizu N, Yamanaka H, Tsuge I, Saito S, Morimoto N. Establishment of a keratinocyte and fibroblast bank for clinical applications in Japan. J Artif Organs 2023;26:45-52. [PMID: 35511369 DOI: 10.1007/s10047-022-01331-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Accepted: 03/27/2022] [Indexed: 10/18/2022]

Outcomes of Patients Treated with Blood Transfusion in a Contemporary Tertiary Care Medical Center Intensive Cardiac Care Unit. J Clin Med 2023;12:jcm12041304. [PMID: 36835840 PMCID: PMC9965353 DOI: 10.3390/jcm12041304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 01/21/2023] [Accepted: 02/03/2023] [Indexed: 02/09/2023] Open

Abstract

BACKGROUND

Acutely ill patients treated with blood transfusion (BT) have unfavorable prognoses. Nevertheless, data regarding outcomes in patients treated with BT admitted into a contemporary tertiary care medical center intensive cardiac care unit (ICCU) are limited. The current study aimed to assess the mortality rate and outcomes of patients treated with BT in a modern ICCU.

METHODS

Prospective single center study where we evaluated mortality, in the short and long term, of patients treated with BT between the period of January 2020 and December 2021 in an ICCU.

OUTCOMES

A total of 2132 consecutive patients were admitted to the ICCU during the study period and were followed-up for up to 2 years. In total, 108 (5%) patients were treated with BT (BT-group) during their admission, with 305 packed cell units. The mean age was 73.8 ± 14 years in the BT-group vs. 66.6 ± 16 years in the non-BT (NBT) group, p < 0.0001. Females were more likely to receive BT as compared with males (48.1% vs. 29.5%, respectively, p < 0.0001). The crude mortality rate was 29.6% in the BT-group and 9.2% in the NBT-group, p < 0.0001. Multivariate Cox analysis found that even one unit of BT was independently associated with more than two-fold the mortality rate [HR = 2.19 95% CI (1.47-3.62)] as compared with the NBT-group, p < 0.0001]. Receiver operating characteristic (ROC) curve was plotted for multivariable analysis and showed area under curve (AUC) of 0.8 [95% CI (0.760-0.852)].

CONCLUSIONS

BT continues to be a potent and independent predictor for both short- and long-term mortality even in a contemporary ICCU, despite the advanced technology, equipment and delivery of care. Further considerations for refining the strategy of BT administration in ICCU patients and guidelines for different subsets of high-risk patients may be warranted.

Collapse

Wang SX, Sun LY, Yu Q, Li T, Li R, Xu YP, Zeng JF. Demographic Factors Among HIV Confirmed Blood Donors from 2013 to 2021 in Shenzhen. Int J Gen Med 2023;16:425-434. [PMID: 36760684 PMCID: PMC9904141 DOI: 10.2147/ijgm.s397236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 01/24/2023] [Indexed: 02/05/2023] Open

Dodd RY, Stramer SL. How do we forecast tomorrow's transfusion: Infectious safety? Transfus Clin Biol 2023;30:35-38. [PMID: 35987477 DOI: 10.1016/j.tracli.2022.08.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]

Belov A, Yang H, Forshee RA, Whitaker BI, Eder AF, Chancey C, Anderson SA. Modeling the Risk of HIV Transfusion Transmission. J Acquir Immune Defic Syndr 2023;92:173-179. [PMID: 36219691 DOI: 10.1097/qai.0000000000003115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 09/19/2022] [Indexed: 01/21/2023]

Faenko AP, Filippova AA, Golosova SA, Glazov YN, Ivanova IV, Klyueva EA, Kasatkin MA. The introduction of Laboratory testing for anti-HBcore in blood donors. RUSSIAN JOURNAL OF HEMATOLOGY AND TRANSFUSIOLOGY 2022. [DOI: 10.35754/0234-5730-2022-67-4-525-534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]

Abstract Introduction. The introduction of screening testing for antibodies to the hepatitis B virus nuclear antigen (anti-HBcore) is designed to prevent the procurement of donated blood from individuals with the latent (occult) form of viral hepatitis B, in which surface HBsAg is not identified.Aim – to evaluate the frequency of anti-HBcore markers’ occurrence in donors under the current regulatory and legal framework.Materials and methods. This retrospective observational study was conducted with a follow-up period of one year among blood donors of the Blood Center (BC) of the Federal Medical-Biological Agency. The screening study for anti-HBcore in blood donors and its components was selective in accordance with the requirements of Appendix № 4 of Order № 1166n of October 28, 2020 of the Ministry of Health of Russia.Results. During the study period, the BC was visited by 17,180 donors who donated blood and its components 35,840 times. There were 181 anti-HBcore tests (0.5 % of all blood samples) in 178 unique donors of blood and blood components (1.03 % of all donors). There were 14 positive, 2 questionable and 166 negative results on anti-HBcore tests. The probability of finding a positive result depending on the conditions was 9 % (7.3–14.7 %). There were no statistically significant differences in the detection of anti-HBcore in primary versus regular donors (OR = 2.539; 95% CI: 0.7321–8; p = 0.13), as well as for male donors compared with female donors (OR = 2.448; 95% CI: 0.7141–11.11; p = 0.17). 86.7 % of donors with a positive test for anti-HBcore previously had no signs of viral hepatitis B disease, the presence of questionable HBsAg was not detected, i. e. these cases may be associated with an occult form. Donors who did not previously have questionable results for various bloodborne infections during their donor career had a slightly higher probability of detecting a positive anti-HBcore test compared to donors who previously had these questionable results (OR = 1.24; 95% CI”: 0.42–3.69; p = 0.69). During the period of the donor career, 233 donations of blood and its components were made by donors with a positive result for anti-HBcore, 468 units of donor components were received, of which 365 units were given to medical institutions.Conclusion. The probability of obtaining a positive test for anti-HBcore in the current regulatory environment is random and does not depend on the results of other infectious markers testing. It is recommended to perform anti-HBcore testing with each donation of blood and blood components. Collapse

Kalibatas V, Kalibatienė L. Reducing the risk of transfusion-transmitted infectious disease markers in blood and blood component donations: Movement from remunerated to voluntary, non-remunerated donations in Lithuania from 2013 to 2020. PLoS One 2022;17:e0277650. [PMID: 36378657 PMCID: PMC9665384 DOI: 10.1371/journal.pone.0277650] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 11/01/2022] [Indexed: 11/16/2022] Open

Myszewski JJ, Rose WN. Educational Case: Perioperative patient blood management. Acad Pathol 2022;9:100057. [PMID: 36262361 PMCID: PMC9573870 DOI: 10.1016/j.acpath.2022.100057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 08/02/2022] [Accepted: 09/03/2022] [Indexed: 11/28/2022] Open

Bloch EM. Deferral of men who have sex with men from blood donation: Policy and change. Transfus Clin Biol 2022;29:195-197. [PMID: 35987530 DOI: 10.1016/j.tracli.2022.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]

Abdallah R, Rai H, Panch SR. Transfusion Reactions and Adverse Events. Clin Lab Med 2021;41:669-696. [PMID: 34689973 DOI: 10.1016/j.cll.2021.07.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]

Bloch EM, Krause PJ, Tonnetti L. Preventing Transfusion-Transmitted Babesiosis. Pathogens 2021;10:pathogens10091176. [PMID: 34578209 PMCID: PMC8468711 DOI: 10.3390/pathogens10091176] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Revised: 09/07/2021] [Accepted: 09/08/2021] [Indexed: 11/16/2022] Open

Wiersum-Osselton J, Prinsze F, van den Brekel E, van Dongen A, Hermans F, Bokhorst A, der Kreek TMV. An intervention study for the prevention of vasovagal reactions and evaluating donors' experience: Analysis of donors' return for subsequent donation. Vox Sang 2021;117:313-320. [PMID: 34396539 DOI: 10.1111/vox.13196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 07/23/2021] [Accepted: 08/03/2021] [Indexed: 11/27/2022]

Abstract

BACKGROUND AND OBJECTIVES

The EPISoDe (Experience Success in Donation) study investigated the effect of interventions on self-reported vasovagal reactions (VVRs) in first-time and novice (second to fourth donation) whole blood donors aged ≤30 years, demonstrating a 23% reduction of VVR from water drinking shortly before donation in the novice donors. Because donation experience and complications affect donor retention, we analysed intervention group donors' return for subsequent donation, a predefined secondary outcome.

MATERIALS AND METHODS

The interventions were as follows: 330 ml water, 500 ml water, ball squeezing before phlebotomy (placebo) and a control group. All donors received an online questionnaire about their experience within a week after donation. In the Netherlands, eligible donors are invited at least yearly depending on hospitals' needs. We analysed attendances within 421 days through return percentages and binomial logistic regression.

RESULTS

Of the 8300 EPISoDe participants, 6538 (78.8%) returned within 421 days. Return did not differ between the two water groups, whereas odds for return were significantly higher in both water and placebo intervention donors compared to the control group (odds ratio [OR] 1.14, 95% confidence interval [CI] 1.00-1.29 and 1.22, 1.05-1.43, respectively) after adjustment for occurrence of VVR, unsuccessful collection, gender and donation history. Staff-recorded or self-reported VVR at index donation was associated with reduced odds for return (OR 0.47, 95% CI 0.37-0.60 and OR 0.53, 95% CI 0.46-0.61, respectively).

CONCLUSION

In this cohort of younger inexperienced blood donors, 78.8% returned for subsequent donation. Donors who received an active study intervention, either water or placebo, were more likely to return than control group donors.

Collapse

Dodd RY, Spencer BR, Xu M, Foster GA, Saá P, Brodsky JP, Stramer SL. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines. Transfus Med Rev 2021;35:1-7. [PMID: 34373145 PMCID: PMC8321690 DOI: 10.1016/j.tmrv.2021.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 06/28/2021] [Accepted: 07/06/2021] [Indexed: 11/26/2022]

Abstract

In the United States, many blood collection organizations initiated programs to test all blood donors for antibodies to SARS-CoV-2, as a measure to increase donations and to assist in the identification of potential donors of COVID-19 convalescent plasma (CCP). As a result, it was possible to investigate the characteristics of healthy blood donors who had previously been infected with SARS-CoV-2. We report the findings from all blood donations collected by the American Red Cross, representing 40% of the national blood supply covering 44 States, in order to characterize the seroepidemiology of SARS-CoV-2 infection among blood donors in the United States, prior to authorized vaccine availability. We performed an observational cohort study from June 15th to November 30th, 2020 on a population of 1.531 million blood donors tested for antibodies to the S1 spike antigen of SARS-CoV-2 by person, place, time, ABO group and dynamics of test reactivity, with additional information from a survey of a subset of those with reactive test results. The overall seroreactivity was 4.22% increasing from 1.18 to 9.67% (June 2020 - November 2020); estimated incidence was 11.6 per hundred person-years, 1.86-times higher than that based upon reported cases in the general population over the same period. In multivariable analyses, seroreactivity was highest in the Midwest (5.21%), followed by the South (4.43%), West (3.43%) and Northeast (2.90%). Seroreactivity was highest among donors aged 18-24 (Odds Ratio 3.02 [95% Confidence Interval 2.80-3.26] vs age >55), African-Americans and Hispanics (1.50 [1.24-1.80] and 2.12 [1.89-2.36], respectively, vs Caucasian). Group O frequency was 51.5% among nonreactive, but 46.1% among seroreactive donors (P< .0001). Of surveyed donors, 45% reported no COVID-19-related symptoms, but 73% among those unaware of testing. Signal levels of antibody tests were stable over 120 days or more and there was little evidence of reinfection. Evaluation of a large population of healthy, voluntary blood donors provided evidence of widespread and increasing SARS-CoV-2 seroprevalence and demonstrated that at least 45% of those previously infected were asymptomatic. Epidemiologic findings were similar to those among clinically reported cases.

Collapse

Retrospective Study of the Seroprevalence of HIV, HCV, and HBV in Blood Donors at a Blood Bank of Western Mexico. Pathogens 2021;10:pathogens10070878. [PMID: 34358028 PMCID: PMC8308904 DOI: 10.3390/pathogens10070878] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 07/08/2021] [Accepted: 07/08/2021] [Indexed: 11/17/2022] Open

Holcomb JB, Spinella PC, Apelseth TO, Butler FK, Cannon JW, Cap AP, Corley JB, Doughty H, Fitzpatrick M, Goldkind SF, Gurney JM, Homer MJ, Ilstrup SJ, Jansen JO, Jenkins DH, Marques MB, Moore EE, Ness PM, O'Connor KC, Schreiber MA, Shinar E, Sloan S, Strandenes G, Stubbs JR, Taylor AL, Ward KR, Waltman E, Yazer M. Civilian walking blood bank emergency preparedness plan. Transfusion 2021;61 Suppl 1:S313-S325. [PMID: 34269450 DOI: 10.1111/trf.16458] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 01/12/2021] [Accepted: 01/14/2021] [Indexed: 12/29/2022]

Affiliation(s)

John B Holcomb Center for Injury Science, Division of Acute Care Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
Philip C Spinella Division of Critical Care, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
Torunn Oveland Apelseth Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway Norwegian Armed Forces Medical Service, Sessvollmoen, Norway
Frank K Butler Uniformed Services University, Bethesda, Maryland, USA
Jeremy W Cannon Division of Traumatology, Surgical Critical Care & Emergency Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Andrew P Cap Uniformed Services University, Bethesda, Maryland, USA US Army Institute of Surgical Research, San Antonio, Texas, USA Ft Sam Houston, San Antonio, Texas, USA
Jason B Corley Army Blood Program, US Army Medical Command, JBSA - Fort Sam Houston, San Antonio, Texas, USA
Heidi Doughty Academic Department of Military Anaesthesia and Critical Care, Royal Centre for Defence Medicine, Birmingham, UK
Michael Fitzpatrick Cellphire Inc., Rockville, Maryland, USA
Sara F Goldkind Goldkind Consulting, L.L.C., Chevy Chase, Maryland, USA
Jennifer M Gurney US Army Institute of Surgical Research, San Antonio, Texas, USA
Mary J Homer Division of Chemical, Biological, Radiological, and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, District of Columbia, USA
Sarah J Ilstrup Department of Laboratory Medicine and Pathology, Intermountain Medical Center, Salt Lake City, Utah, USA
Jan O Jansen Division of Acute Care Surgery; and Director, Center for Injury Science, University of Alabama at Birmingham, Birmingham, Alabama, USA
Donald H Jenkins Division of Trauma and Emergency Surgery, UT Health, San Antonio, Texas, USA
Marisa B Marques Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Eugene E Moore Shock Trauma Center at Denver Health, Department of Surgery, University of Colorado Denver, Denver, Colorado, USA
Paul M Ness Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Kevin C O'Connor George Washington University School of Medicine and Health Sciences, Medical Faculty Associates, Washington, District of Columbia, USA
Martin A Schreiber Oregon Health & Science University, Portland, Oregon, USA
Eilat Shinar Ben Gurion University, Beersheba, Israel
Steve Sloan Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Geir Strandenes Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway Department of War Surgery and Emergency Medicine, Norwegian Armed Forces Medical Services, Oslo, Norway
James R Stubbs Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA
Audra L Taylor Armed Services Blood Program, Defense Health Agency, Falls Church, Virginia, USA
Kevin R Ward George Washington University School of Medicine and Health Sciences, Medical Faculty Associates, Washington, District of Columbia, USA
Elizabeth Waltman BioBridge Global, Inc., San Antonio, Texas, USA South Texas Blood & Tissue Center, San Antonio, Texas, USA
Mark Yazer University of Pittsburgh, Pittsburgh, Pennsylvania, USA Tel Aviv University, Tel Aviv, Israel University of Southern Denmark, Odense, Denmark

Collapse

Nishiya AS, Levi JE, de Almeida-Neto C, Witkin SS, Ferreira SC, Bassit L, Sabino EC, Di-Lorenzo-Oliveira C, Salles NA, Coutinho AS, Bellesa MA, Rocha V, Mendrone-Jr A. Occult and active hepatitis B virus detection in donated blood in São Paulo, Brazil. Transfusion 2021;61:1495-1504. [PMID: 33687074 DOI: 10.1111/trf.16344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 02/04/2021] [Accepted: 02/04/2021] [Indexed: 12/16/2022]

Affiliation(s)

Anna S Nishiya Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Oncoimmunohematology (LIM-31), Department of Hematology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
José E Levi Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil
Cesar de Almeida-Neto Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Disciplina de Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil
Steven S Witkin Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil.,Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York, USA
Suzete C Ferreira Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Oncoimmunohematology (LIM-31), Department of Hematology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Leda Bassit Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA
Ester C Sabino Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil.,Disciplina de Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil
Claudia Di-Lorenzo-Oliveira University of São João del Rei, Divinópolis, Brazil
Nanci A Salles Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil
Adenilson S Coutinho Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil
Maria A Bellesa Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil
Vanderson Rocha Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Oncoimmunohematology (LIM-31), Department of Hematology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.,Disciplina de Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.,Churchill Hospital, Oxford University, Oxford, UK
Alfredo Mendrone-Jr Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Oncoimmunohematology (LIM-31), Department of Hematology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Collapse

Steele WR, Dodd RY, Notari EP, Haynes J, Anderson SA, Williams AE, Reik R, Kessler D, Custer B, Stramer SL. HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion 2021;61:839-850. [PMID: 33460470 DOI: 10.1111/trf.16250] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 11/17/2020] [Accepted: 11/17/2020] [Indexed: 12/19/2022]

Goel R, Petersen MR, Patel EU, Packman Z, Bloch EM, Gehrie EA, Lokhandwala PM, Ness PM, Shaz B, Katz LM, Frank SM, Tobian AAR. Comparative changes of pre-operative autologous transfusions and peri-operative cell salvage in the United States. Transfusion 2020;60:2260-2271. [PMID: 32869327 PMCID: PMC7902373 DOI: 10.1111/trf.15949] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 06/16/2020] [Accepted: 06/16/2020] [Indexed: 01/28/2023]

Abstract

BACKGROUND

With improved safety of allogeneic blood supply, the use of preoperative autologous donations (PADs) and perioperative autologous cell salvage (PACS) has evolved. This study evaluated temporal trends in PAD and PACS use in the United States.

METHODS

The National Inpatient Sample database, a stratified probability sample of 20% of hospitalizations in the United States, was used to compare temporal trends in hospitalizations reporting use of PADs and PACS from 1995 to 2015. Factors associated with their use were examined between 2012 and 2015 with use of multivariable Poisson regression. Sampling weights were applied to generate nationally representative estimates.

RESULTS

There was a steady decrease in hospitalizations reporting PAD transfusions from 27.90 per 100 000 in 1995 to 1.48 per 100 000 hospitalizations in 2015 (P-trend <.001). In contrast, PACS increased from a rate of 1.16 per 100 000 in 1995 to peak of 20.51 per 100 000 hospitalizations in 2008 and then steadily declined (P-trend<.001). Higher odds of PACS and PADs were observed in older patients, elective procedures (vs urgent), and urban teaching/nonteaching hospitals (vs rural hospitals) (P < .001). PACS was more common in hospitalizations in patients with higher levels of severity of illness as compared to those with minor severity (adjusted prevalence ratio [adjPR], 2.39; 95% confidence interval [CI], 2.08-2.73; P<.001), while PADs were performed less often in patients with higher underlying severity of illness (All Patient Refined Diagnosis Related Groups, 4 vs 1, adjPR, 0.61; 95% CI, [0.39-0.95]; P = .028).

CONCLUSIONS

There was a significant decrease in PAD red blood cell transfusions, while PACS has increased and subsequently decreased; PACS plays an important role in surgical blood conservation. The subsequent decline in PACS likely reflects further optimization of transfusion practice through patient blood management programs and improvement of surgical interventions.

Collapse

Grebe E, Busch MP, Notari EP, Bruhn R, Quiner C, Hindes D, Stone M, Bakkour S, Yang H, Williamson P, Kessler D, Reik R, Stramer SL, Glynn SA, Anderson SA, Williams AE, Custer B. HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men. Blood 2020;136:1359-1367. [PMID: 32693408 PMCID: PMC7483431 DOI: 10.1182/blood.2020007003] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 07/07/2020] [Indexed: 12/29/2022] Open

Abstract

In 2015, the US Food and Drug Administration published revised guidance that recommended a change in blood donor deferral of men who have sex with men (MSM) from an indefinite to a 12-month deferral since the donor last had sex with a man. We assessed whether HIV incidence in first-time blood donors or associated transfusion risk increased. Donations in 4 major blood collection organizations were monitored for 15 months before and 2 years after implementation of the 12-month MSM deferral policy. HIV-positive donations were classified as recently acquired or long-term using a recent infection testing algorithm and incidence in both periods estimated. Residual transfusion transmission risk was estimated by multiplying incidence by the length of the infectious window period. The latter was estimated using a model based on infectious dose and the sensitivity of nucleic acid testing. Factors associated with incident infection in each period were assessed using Poisson regression. Overall HIV incidence in first-time donors before implementation of the 12-month MSM deferral was estimated at 2.62 cases per 100 000 person-years (105 PY) (95% credible interval [CI], 1.53-3.93 cases/105 PY), and after implementation at 2.85 cases/105 PY (95% CI, 1.96-3.93 cases/105 PY), with no statistically significant change. In male first-time donors, the incidence difference was 0.93 cases/105 PY (95% CI, -1.74-3.58 cases/105 PY). The residual risk of HIV transfusion transmission through components sourced from first-time donors was estimated at 0.32 transmissions per million (106) packed red blood cell transfusions (95% CI, 0.29-0.65 transmissions/106 transfusions) before and 0.35 transmissions/106 transfusions (95% CI, 0.31-0.65 transmissions/106 transfusions) after implementation. The difference was not statistically significant. Factors associated with incident infection were the same in each period. We observed no increase in HIV incidence or HIV transfusion transmission risk after implementation of a 12-month MSM deferral policy.

Collapse

Piyush R, Rajarshi K, Khan R, Ray S. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open Biol 2020;10:200174. [PMID: 32898468 PMCID: PMC7536086 DOI: 10.1098/rsob.200174] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Accepted: 08/18/2020] [Indexed: 12/13/2022] Open

Steele WR, Dodd RY, Notari EP, Xu M, Nelson D, Kessler DA, Reik R, Williams AE, Custer B, Stramer SL. Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: The Transfusion-Transmissible Infections Monitoring System (TTIMS). Transfusion 2020;60:2327-2339. [PMID: 32869326 DOI: 10.1111/trf.16005] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 06/08/2020] [Accepted: 06/08/2020] [Indexed: 12/14/2022]

Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, Rojas-Villarraga A, Ramírez-Santana C, Díaz-Coronado JC, Manrique R, Mantilla RD, Shoenfeld Y, Anaya JM. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020. [PMID: 32380316 DOI: 10.1016/j.autrev.2020.102554.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Affiliation(s)

Manuel Rojas Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Yhojan Rodríguez Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia
Diana M Monsalve Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Yeny Acosta-Ampudia Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Bernardo Camacho Instituto Distrital de Ciencia Biotecnología e Investigación en Salud, IDCBIS, Bogota, Colombia
Juan Esteban Gallo Genoma CES, Universidad CES, Medellin, Colombia
Adriana Rojas-Villarraga Fundación Universitaria de Ciencias de la Salud (FUCS), Bogota, Colombia
Carolina Ramírez-Santana Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Juan C Díaz-Coronado Internal Medicine Department, Universidad CES, Medellin, Colombia
Rubén Manrique Epidemiology and Biostatistics Research Group, Universidad CES, Medellin, Colombia
Ruben D Mantilla Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia
Yehuda Shoenfeld Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Tel-Aviv University, Tel Aviv, Israel; Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russian Federation
Juan-Manuel Anaya Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia.

Collapse

Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, Rojas-Villarraga A, Ramírez-Santana C, Díaz-Coronado JC, Manrique R, Mantilla RD, Shoenfeld Y, Anaya JM. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020;19:102554. [PMID: 32380316 PMCID: PMC7198427 DOI: 10.1016/j.autrev.2020.102554] [Citation(s) in RCA: 309] [Impact Index Per Article: 61.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Accepted: 04/12/2020] [Indexed: 12/17/2022]

Affiliation(s)

Manuel Rojas Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Yhojan Rodríguez Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia
Diana M Monsalve Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Yeny Acosta-Ampudia Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Bernardo Camacho Instituto Distrital de Ciencia Biotecnología e Investigación en Salud, IDCBIS, Bogota, Colombia
Juan Esteban Gallo Genoma CES, Universidad CES, Medellin, Colombia
Adriana Rojas-Villarraga Fundación Universitaria de Ciencias de la Salud (FUCS), Bogota, Colombia
Carolina Ramírez-Santana Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Juan C Díaz-Coronado Internal Medicine Department, Universidad CES, Medellin, Colombia
Rubén Manrique Epidemiology and Biostatistics Research Group, Universidad CES, Medellin, Colombia
Ruben D Mantilla Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia
Yehuda Shoenfeld Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Tel-Aviv University, Tel Aviv, Israel; Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russian Federation
Juan-Manuel Anaya Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia.

Collapse